{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:51:47Z","timestamp":1781221907204,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ranolazine, a piperazine derivative, is used as a second-line treatment for individuals with stable or poorly managed chronic angina as well as for those whose chronic angina is not improving with other medications. However, there is still a lack of real-world evidence on the long-term safety of its adverse events (AEs), which calls for constant supplementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study conducted disproportionality analysis to evaluate the safety of ranolazine in clinical practice by utilizing data from the FDA Adverse Event Reporting System (FAERS). Reporting Odds Ratio, Proportional Reporting Ratio, Multi-item Gamma Poisson Shrinker and Bayesian Confidence Propagation Neural Network were used to identify signals of possible adverse events linked to ranolazine. Additionally, the Weibull distribution was implemented to simulate how the frequency of adverse events changed over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Positive signals were found for adverse events listed on the medication label, including dizziness, nausea, asthenia, constipation, headache, palpitations, tinnitus, abdominal pain, dry mouth, vomiting, peripheral edema, dyspnea and hypotension. Additionally, potential side effects not included on the label were also identified, including chest pain, cardiac disorder, electrocardiogram qt prolonged, hypertension, seizure, tremor, atrial fibrillation, coronary artery disease, pulmonary embolism, myoclonus and myocardial infarction. The significance of tracking adverse events was underlined, especially during the first month after the start of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study has confirmed certain known adverse effects and identified other potential hazards by providing preliminary safety data on the practical use of ranolazine. The results present vital safety information for physicians prescribing ranolazine. Notably, this study only identifies safety signals and does not establish causal relationships between ranolazine and the observed adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1702875","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:09Z","timestamp":1762756269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Zujun","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengliang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1056\/NEJMcp042317","article-title":"Clinical practice. Chronic stable angina","volume":"352","author":"Abrams","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin. drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.Cir.0000139333.83620.5d","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41569-021-00573-w","article-title":"A pathophysiological compass to personalize antianginal drug treatment","volume":"18","author":"Bertero","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/heart.87.2.140","article-title":"Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population","volume":"87","author":"Brorsson","year":"2002","journal-title":"Heart British Card. Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijcard.2014.12.055","article-title":"Ranolazine: drug overview and possible role in primary microvascular angina management","volume":"181","author":"Cattaneo","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mus.27560","article-title":"Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis","volume":"66","author":"Chandrashekhar","year":"2022","journal-title":"Muscle & nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7093","DOI":"10.1021\/jm501981g","article-title":"Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications","volume":"58","author":"de Lera Ruiz","year":"2015","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10517-024-06156-2","article-title":"Effects of ranolazine and ivabradine on pulmonary microhemodynamics in experimental model of pulmonary thromboembolism","volume":"177","author":"Evlakhov","year":"2024","journal-title":"Bull. Exp. Biol. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"894685","DOI":"10.3389\/fphar.2022.894685","article-title":"Real-world safety of PCSK9 inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS","volume":"13","author":"Feng","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hrthm.2016.10.008","article-title":"Role of ranolazine in the prevention and treatment of atrial fibrillation: a meta-analysis of randomized clinical trials","volume":"14","author":"Gong","year":"2017","journal-title":"Heart rhythm."},{"key":"B14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00392-014-0796-x","article-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","volume":"104","author":"Hammond","year":"2015","journal-title":"Clin. Res. Cardiol. official J. Ger. Cardiac Soc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s00392-007-0612-y","article-title":"Mechanism of action of the new anti-ischemia drug ranolazine","volume":"97","author":"Hasenfuss","year":"2008","journal-title":"Clin. Res. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-World adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2019","journal-title":"Eur. heart J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/europace\/eut407","article-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace: european pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the","volume":"16","author":"Koskinas","year":"2014","journal-title":"Eur. Soc. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2131\/jts.49.231","article-title":"Novel predictive approaches for drug-induced convulsions in non-human primates using machine learning and heart rate variability analysis","volume":"49","author":"Kuga","year":"2024","journal-title":"J. Toxicol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/diseases9020031","article-title":"Role of ranolazine in the prevention and treatment of atrial fibrillation in patients with left ventricular systolic dysfunction: a meta-analysis of randomized clinical trials","volume":"9","author":"Leelapatana","year":"2021","journal-title":"Dis. Basel, Switz."},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejim.2021.08.003","article-title":"State of the art approach to managing angina and ischemia: tailoring treatment to the evidence","volume":"92","author":"Manolis","year":"2021","journal-title":"Eur. J. Intern. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/s0140-6736(08)61554-8","article-title":"Ranolazine for chronic stable angina","volume":"372","author":"Nash","year":"2008","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3390\/jcm13061672","article-title":"Real-world data from the use of ranolazine in patients with stable angina pectoris: the RANGER study","volume":"13","author":"Olympios","year":"2024","journal-title":"J. Clin. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J. Clin. Endocrinol. metabolism"},{"key":"B27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int. J. Med. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40256-020-00462-6","article-title":"Use of ranolazine for the treatment of coronary microvascular dysfunction","volume":"21","author":"Sharp","year":"2021","journal-title":"Am. J. Cardiovasc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2025.03.017","article-title":"The real-world safety profile of sertraline: pharmacovigilance analysis of the FAERS database","volume":"379","author":"Shu","year":"2025","journal-title":"J. Affect. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.jacc.2009.12.055","article-title":"Altered na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium","volume":"55","author":"Sossalla","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2174\/138161213805219612","article-title":"Insight to the pathophysiology of stable angina pectoris","volume":"19","author":"Tousoulis","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"B34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/pace.13048","article-title":"Ranolazine added to amiodarone facilitates earlier conversion of atrial fibrillation compared to amiodarone-only therapy","volume":"40","author":"Tsanaxidis","year":"2017","journal-title":"Pacing Clin. Electrophysiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and vigiBase(\u00ae)","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.jacc.2009.01.037","article-title":"Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (metabolic efficiency with ranolazine for less ischemia in Non-ST-Segment elevation acute coronary syndromes) 36 trial","volume":"53","author":"Wilson","year":"2009","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1702875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:10Z","timestamp":1762756270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1702875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1702875"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1702875","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1702875"}}